SABCS and ASH findings: palbociclib improves PFS in HR+, HER2+ breast cancer, cilta-cel achieves 100% CR in smoldering MM, and selinexor with ruxolitinib aids myelofibrosis.

CDK4/6) in metastatic breast cancer prolongs time on treatment but does not improve patient outcomes. Postponing innovative treatments to a later stage of the disease could thus safely reduce the ...

The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...

Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations, and 23% maturity among all patients, ...

Among the many promising advances in breast cancer treatment in recent years are CDK4/6 inhibitors. These are targeted drugs that can be used for women with a common type of breast cancer ...

SAN ANTONIO — For patients with advanced hormone receptor-positive, HER2-negative breast cancer, health-related quality of life is the same whether they receive CDK4/6 inhibitors in the first or ...

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either ...

Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, ...

An experimental drug stops advanced breast cancer from progressing in some people with tumors that have grown resistant to ...

There is a huge need to identify patients who may or may not benefit from adding CDK4/6 inhibitors at the time of metastatic diagnosis to guide escalation and de-escalation strategies in advance ...